-
Company Insights
Innovation and Patenting activity of KH Neochem Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of KH Neochem Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KH-631 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KH-631 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KH-631 in Wet (Neovascular / Exudative) Macular Degeneration Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IBI-345 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IBI-345 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IBI-345 in Gastric Cancer Drug Details: IBI-345 is under development for...
-
Product Insights
Anal Fistula – Drugs In Development, 2023
Global Markets Direct’s, ‘Anal Fistula - Drugs In Development, 2023’, provides an overview of the Anal Fistula pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anal Fistula , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
Radiation Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Injury - Drugs In Development, 2023’, provides an overview of the Radiation Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Fistula – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Fistula - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Fistula pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Fistula , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drugs In Development, 2023’, provides an overview of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGBB-167 in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BGBB-167 in Colorectal Cancer Drug Details: BGBB-167 is under development for the treatment of advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HFB-200603 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HFB-200603 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HFB-200603 in Non-Small Cell Lung Cancer Drug Details: HFB-200603...